Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Vaccination in advanced age].

Der Internist·2017
Same author

European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

Burden of Disease Caused by Influenza in Germany - A Retrospective Claims Database Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.

Geburtshilfe und Frauenheilkunde·2016
Same author

[Communication from the German Association for the Control of Viral Diseases. (DVV) and the Robert Koch Institute (RKI) Publication of the updated version of the guideline for testing chemical disinfectants for effectiveness against viruses in human medicine (suspension test) - version December 1, 2014].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2015
Same journal

Corneal Neurotisation in Neurotrophic Keratopathy: A Retrospective Analysis of Functional Outcomes and Clinical Courses.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Evaluating the Long-term Success and Safety of Canaloplasty in Glaucoma Patients.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Imbalanced Trace Elements as Risk Factors in the Pathogenesis of Glaucoma.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Malnutrition as a Risk Factor for Cerebral and Glaucomatous Neurodegeneration - Mechanisms and Therapeutic Strategies.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

Impact of Wearing a Face Mask on the Reliability of Standard Automated Perimetry in Glaucoma Patients and Suspects: a Retrospective Longitudinal Study.

Klinische Monatsblatter fur Augenheilkunde·2026
Same journal

[Siderotic Cataract Eight Months After Intralenticular Metallic Foreign Body: A Case Report and Surgical Management].

Klinische Monatsblatter fur Augenheilkunde·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

[Zoster vaccine].

P Wutzler1

  • 1Institut für Virologie und Antivirale Therapie, Universitätsklinikum Jena, Jena, Germany. Peter.Wutzler@med.uni-jena.de

Klinische Monatsblatter Fur Augenheilkunde
|May 22, 2010
PubMed
Summary
This summary is machine-generated.

The Zostavax vaccine significantly reduces herpes zoster and postherpetic neuralgia (PHN) in adults over 60. This vaccine offers substantial protection against shingles and its complications, with benefits lasting at least seven years.

More Related Videos

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Related Experiment Videos

Last Updated: Jun 12, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Area of Science:

  • Immunology
  • Vaccinology
  • Epidemiology

Context:

  • Herpes zoster (shingles) and its complication, postherpetic neuralgia (PHN), pose a significant health burden, particularly in older adults.
  • The availability of Zostavax, an attenuated live varicella-zoster virus vaccine, offers a preventative strategy for this population.
  • Understanding the real-world efficacy and safety of Zostavax is crucial for public health recommendations.

Purpose:

  • To evaluate the efficacy and safety of the Zostavax vaccine in preventing herpes zoster and PHN in adults aged 60 years and older.
  • To assess the vaccine's impact on the overall burden of illness associated with herpes zoster.
  • To determine the duration of vaccine protection and its tolerability.

Summary:

  • A large-scale, double-blind, randomized, placebo-controlled trial involving over 38,000 immunocompetent adults aged 60+ demonstrated Zostavax efficacy.
  • The vaccine reduced herpes zoster by 51% and PHN incidence by 67%, leading to a 61% overall reduction in disease burden.
  • Vaccine efficacy decreased with age, but older individuals (70+) still experienced considerable benefits; protection persists for at least 7 years.

Impact:

  • Zostavax vaccination significantly lowers the incidence and severity of herpes zoster and PHN in older adults.
  • The vaccine is well-tolerated and can be co-administered with inactivated influenza vaccine, though not with pneumococcal vaccine.
  • These findings support the use of Zostavax as an effective tool in managing the burden of herpes zoster in elderly populations.